As nuclear Trx1 is required for NF-κB activation, DMF impairs NF-κB signaling in T-cell lymphomas with constitutive pathway activity, such as T-cell acute lymphoblastic leukemia (T-ALL) and cutaneous T-cell lymphoma (CTCL). This evidence concerns the gene NFKB1 and acute lymphoblastic leukemia.